Israel’s Teva Pharmaceutical Industries is increasing its stake in biotechnology company MediWound Ltd to 51% under a multi-tiered deal to develop and commercialise products to treat burns and wounds.
Teva increases stake in Mediwound to 51%
Home/Pharma News | Posted 11/02/2011 0 Post your comment
The world’s largest generics manufacturer is joining forces with Israel-based MediWound, which is purchasing wound management company Polyheal Ltd, under a partnership that aims to combine the latter’s products and expertise with MediWound’s technology and production capabilities and Teva’s global marketing presence.
According to the agreement, Teva will purchase shares from MediWound's shareholders for US$10 million and will invest an additional US$5 million in exchange for shares issued by MediWound. Teva in return will obtain an exclusive license to market and distribute Debrase (MediWound’s innovative enzymatic product for the removal of dead tissue from burn wounds) in certain countries.
Investment group Clal Biotechnology Industries, which currently holds 55% of MediWound and 41% of Polyheal, said MediWound would acquire all of Polyheal in stages for US$200 million, according to Reuters.
In later stages of the deal, Teva, who now hold 12% of MediWounds shares, may purchase up to 51% of MediWound’s shares, based on a company valuation of US$300 million.
The rather complicated, multi-stage deal means that Teva will pay MediWound US$167 million plus royalties for exclusive rights to sell Polyheal’s products, which include technologies for treating difficult to heal wounds such as burns and ulcers, giving the firm access to a global wound management market estimated at US$9 billion per year.
Source: MediWound, Reuters.
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
EMS proposes merger with Hypera to form Brazil's largest drugmaker
Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206
Advances for Biocon Biologics’ Stelara and Eylea biosimilars
Comments (0)
Post your comment